A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Injection of LY-N001 Injection for the Treatment of Moderate to Advanced Parkinson's Disease With GBA1 Mutations

Official title

A Prospective, Single-Arm, Single-Dose Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Administration of LY-N001 Injection in Subjects With Moderate to Advanced Parkinson's Disease Carrying GBA1 Mutations

Overview

This is a prospective, single-arm, single-dose clinical study designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-N001 Injection in patients with moderate-to-advanced Parkinson's disease carrying GBA1 mutations. The study consists of a main study phase and a long-term follow-up phase.

Detailed description

This is a prospective, single-arm, single-dose clinical study designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-N001 Injection in patients with moderate-to-advanced Parkinson's disease carrying GBA1 mutations. The study consists of a main study phase and a long-term follow-up phase.

Three dose cohorts are pre-specified in this study, including a de-escalation dose cohort (0.5 × 10¹¹ vg/g brain weight), a low-dose cohort (1.0 × 10¹¹ vg/g brain weight), and a high-dose cohort (2.0 × 10¹¹ vg/g brain weight). The low-dose cohort serves as the starting dose of this study, and the dose design is presented in Table 1. The first participant will be enrolled at the starting dose of 1.0 × 10¹¹ vg/g brain weight. Subsequent participants will be enrolled only after safety confirmation following the DLT observation period.

Interventions

• Genetic LY-N001 Injection
  LY-N001 Injection shall be administered as a single intracerebroventricular (ICV) injection, with one administration only

Primary outcome measures

• Incidence of dose-limiting toxicity (DLT) events occurring within at least 28 days following a single intracranial administration of LY-N001 [Time frame: Within 28 days post-administration]
• Incidence of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) occurring during the treatment period [Time frame: Within 52 weeks post-administration]

Secondary outcome measures (12)

• Change from baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) motor examination scores during OFF and ON medication states [Time frame: Within 52 weeks post-administration]
• Parkinson's disease medication use: changes in daily oral levodopa (L-DOPA) dose or levodopa equivalent dose (LED) [Time frame: within 52 weeks post-administration]
• Motor fluctuations assessed via patient diaries: changes in "ON" time without dyskinesia or without troublesome dyskinesia, and changes in "OFF" time [Time frame: Within 52 weeks post-administration]
• Changes in scores of the MDS Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part I, MDS-UPDRS Part II and MDS-UPDRS Part IV) [Time frame: Within 52 weeks post-administration]
• Change from baseline in Mini-mental State Examination (MMSE) score [Time frame: Within 52 weeks post-administration]
• Change from baseline in Montreal Cognitive Assessment (MoCA) score [Time frame: Within 52 weeks post-administration]
• Change from baseline in Geriatric Depression Scale (GDS) score [Time frame: Within 52 weeks post-administration]
• Change from baseline in Parkinson's Disease Sleep Scale-2 (PDSS-2) score [Time frame: Within 52 weeks post-administration]
• Change from baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) score [Time frame: Within 52 weeks post-administration]
• Change from baseline in Dopamine Transporter Positron Emission Tomography (DAT-PET) and Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) parameters. [Time frame: Within 52 weeks post-administration]
• Change from baseline in blood glucocerebrosidase (GCase) activity level [Time frame: Within 52 weeks post-administration]
• Change from baseline in blood lyso-glucosylsphingosine (Lyso-GL1) levels [Time frame: Within 52 weeks post-administration]

Eligibility criteria

Inclusion criteria

• Aged 30 to 70 years inclusive; both males and females are eligible.
• The participant fully understands the purpose, nature, procedures of the study and potential adverse events, voluntarily agrees to take part in the study and signs the informed consent form (ICF).
• Participants with clinically diagnosed idiopathic Parkinson's disease (PD) meeting the 2015 Movement Disorder Society (MDS) diagnostic criteria for idiopathic PD.
• Participants carrying at least one pathogenic GBA1 variant.
• Duration of PD disease ≥ 3 years.
• Off-state Hoehn-Yahr stage ranges from 2.5 to 4.
• Neutralizing antibody titer against AAV ≤ 1:200.
• The off-state MDS-UPDRS Part III (see Appendix 6 for MDS-UPDRS Part III motor examination) score is greater than 25, with either a ≥30% improvement rate on the acute levodopa challenge test, or an average daily off time of ≥2.5 hours over 3 consecutive days.
• Investigators determined that patients must receive a stable dose of dopaminergic medications, including levodopa, for a minimum of 4 weeks prior to surgery.
• Acceptable laboratory test values shall be obtained during the screening period and prior to administration (Day -3)：a).Hemoglobin ≥ 100 g/L; b).Platelets ≥ 100 × 10⁹/L; c). Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) ≤ 2 × upper limit of normal (ULN); d).Total bilirubin ≤ 2 × upper limit of normal (ULN); e).Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min.
• Demonstrates good treatment adherence and ability to attend scheduled follow-up visits; the participant shall be capable of accurately completing the Parkinson's disease (PD) diary during follow-up, or the participant's family member, legal guardian or caregiver may assist with diary completion.
• The participant agrees to postpone any other planned elective neurosurgical procedures (excluding emergent life-threatening neurosurgical operations occurring during the study), including Deep Brain Stimulation (DBS), until completion of the 52-week follow-up period, unless DBS treatment is recommended by a specialist in the participant's best interest.
• The participant agrees not to participate in any other therapeutic intervention studies during the study period and shall not take any other medications that may interfere with treatment other than those specified in the protocol.
• The participant agrees to refrain from receiving any vaccinations within 30 days after surgery.
• The participant must be willing to refrain from donating blood, organs, tissues or cells at any time following treatment administration.
• Female participants of childbearing potential (WOCBP) must have a negative pregnancy test.
• The participant and their partner have no plans to conceive from screening through 6 months after study completion, and will voluntarily use effective contraceptive measures (such as abstinence, condoms, etc.); the participant has no intention to donate sperm or ova.

Exclusion criteria

• Atypical or secondary parkinsonism (including Parkinson-plus syndromes, hereditary parkinsonism, drug-induced parkinsonism, etc.).
• Patients with clinically confirmed LRRK2 mutation.
• Previous history of pallidotomy, Deep Brain Stimulation (DBS) surgery, striatal surgery, extrapyramidal surgery, stereotactic brain surgery or other brain surgeries; or any other surgical history judged by the investigators to interfere with the subject's participation in this study.
• Participants with previous head Computed Tomography (CT) / Magnetic Resonance Imaging (MRI) showing neurological diseases such as brain trauma, vascular malformations, hydrocephalus, brain tumors; subjects with hyperintense white matter signals on MRI indicating risk of intracranial hemorrhage; subjects with cerebrovascular lesions or microbleeds on SWI (Susceptibility-Weighted Imaging); subjects with vulnerable plaques or intraplaque hemorrhage of craniocervical arteries on HR-MRI (High-Resolution Magnetic Resonance Imaging); or subjects with imaging abnormalities in the striatum or other brain regions that substantially increase surgical risks.
• The participant has a Mini-Mental State Examination (MMSE) score of less than 20.
• A Patient Health Questionnaire (PHQ) score of ≥16 indicates severe depression.
• Any severe psychiatric illnesses including epilepsy, severe anxiety, schizophrenia that are deemed unsuitable for participation in this study by the investigators, excluding mild hallucinations and similar symptoms induced by anti-Parkinsonian medications.
• Patients taking anticoagulants or antiplatelet drugs whose coagulation function has not returned to normal 10 days after drug discontinuation.
• Patients who have previously received gene therapy or cell therapy.
• Use of systemic glucocorticoids or immunosuppressive drugs within 12 weeks prior to administration, except for prophylactic immunosuppressive agents required by the protocol (excluding prophylactic immunosuppressive therapy specified in the protocol).
• Participants with unstable cardiovascular and cerebrovascular diseases, defined as clinical cardiovascular and cerebrovascular events occurring within 3 months prior to screening (e.g., unstable angina, myocardial infarction, stroke, etc.); uncontrolled diabetes mellitus with glycated hemoglobin >8.0%; or other unstable acute or chronic diseases including infectious diseases, severe uncontrolled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg), or severe orthostatic hypotension (a drop in systolic blood pressure ≥20 mmHg or diastolic blood pressure ≥10 mmHg within 3 minutes after the participant changes from supine/squatting position to standing position).
• Positive Hepatitis B surface antigen (HBsAg) or Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA); positive Hepatitis C Virus antibody (HCV-Ab) or Hepatitis C Virus Ribonucleic Acid (HCV-RNA).For participants with a prior history of hepatitis B or hepatitis C, two samples collected at an interval of at least 3 months must test negative for all above indicators to be considered negative. Participants with spontaneously cleared or antivirally treated cleared hepatitis B or C are eligible for this study.Participants with positive Human Immunodeficiency Virus (HIV) test or positive syphilis serology.
• Participants with surgical contraindications, those who have received other surgical procedures deemed to interfere with this study by the investigators within six months, or those with other contraindications to neurosurgery.
• Participants with an average weekly alcohol intake exceeding 21 units for males or 14 units for females within 30 days prior to screening; 1 alcohol unit equals one 5 oz (150 mL) glass of red wine, 12 oz (360 mL) beer, or 1.5 oz (45 mL) distilled spirits; or participants with a history of drug dependence.
• Participants with contrast medium allergy who cannot undergo MRI, or those unable to tolerate surgical anesthesia.
• Participants with hypersensitivity to LY-N001 Injection.
• History of cancer within 5 years prior to screening, excluding completely resected non-melanoma skin cancer, non-metastatic prostate cancer, fully cured carcinoma in situ, and papillary thyroid carcinoma cured after radical surgical resection.
• Pregnant women, women planning pregnancy, or breastfeeding women.
• Participants who are currently enrolled in another clinical trial, or those who participated in another clinical trial and received investigational products within one month.
• Participants who are deemed ineligible for enrollment upon investigator's assessment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• The First Affiliated Hospital of Anhui Medical University — Hefei

Identifiers

NCT: NCT07685444 · LY-N001-PD-IIT-001-1

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗